In the article, Perehudoff argues that the EU is deliberately leveraging its internal market to encourage pharmaceutical companies to improve global access to antimicrobials and reduce antimicrobial resistance caused by medicines manufacturing outside Europe. 

The proposed reforms—including mandatory disclosure of public R&D subsidies for new medicines and the introduction of transferable data exclusivity vouchers—may unintentionally influence pharmaceutical policy decisions in countries outside the EU. At the same time, they offer opportunities for non-EU countries to use transparency measures to negotiate lower medicine prices and improve access to novel antimicrobials. 

The global impact of EU policy is often overlooked, especially in light of developments in the United States, where public datasets are being purged and funding for medicines testing is being cut. This study contributes to the growing body of research on how EU pharmaceutical legislation affects global medicines markets and access.